• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Hip and Knee News

News Resource About Hip, Knee and Orthopedic Surgery

  • Home
  • Hip Surgery
  • Knee Surgery
  • Resources
    • Hip and Knee Glossary
  • About/Contact

OrthoTrophix Presents New Data Suggesting Joint Bone Shape as a Possible Surrogate Marker for Virtual Joint Replacement in Knee Osteoarthritis

by

FOSTER CITY, Calif., April 8, 2022 /PRNewswire/ — OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company and its collaborators present clinical data strongly supporting joint bone shape change as part of a surrogate marker predictive of joint replacement in knee osteoarthritis (OA) patients.

An abstract entitled, “Improved WOMAC Physical Function is Associated with Slowed Pathological Bone Shape Change after TPX-100: Towards a Surrogate Marker for Virtual Knee Replacement?” was presented today in a Plenary Session of 2022 OARSI World Congress on Osteoarthritis in Berlin, Germany (Abstract 26 in Osteoarthritis and Cartilage Vol. 30 Suppl. S28–S29).

Functional impairment is a key risk factor for knee replacement even after adjusting for knee pain severity, based on the large NIH-sponsored Multicenter Osteoarthritis Study (the “MOST” study) involving over 5,500 knees. In the TPX-100-5, a Phase 2 study, placebo-treated knees with more advanced pathological joint bone shape change at baseline showed much faster progression of pathological bone shape change and poorer knee function at the end of the 12-month study period. In marked contrast, TPX-100-treated knees demonstrated reduction in pathological bone shape change and robust improvement of knee function through 12 months, regardless of severity at baseline. Consequently, both clinical (knee function) and structural (bone shape) efficacies of TPX-100 as compared to placebo were confirmed including in subjects with moderate to severe knee OA.

“The current FDA draft guidance indicates that a positive effect on an imaging marker of OA must be associated with avoidance or delay of the need for joint replacement, or must persuasively reduce deterioration of function and worsening of pain. This is a high bar,” commented Dr. Dawn McGuire, OrthoTrophix’ Chief Medical Officer. “However, the Multicenter Osteoarthritis Study findings and our clinical data collectively suggest that concordant improvements of bone shape change and clinical function could lead to a delay or elimination of the need for joint replacement surgery. These combined outcomes in structure and function could provide a ‘virtual joint replacement’ measure for the study of disease-modifying agents in individuals afflicted with knee OA.”

The Company also will present an abstract entitled, “Intra Articular TPX-100 Significantly Improves Pain Measures and Slows Pathological Bone Shape Chage in Knee OA”. This presentation demonstrates clinically meaningful improvements in overall knee pain and in specific key pain parameters in moderate to severe knee OA, linked to significant reductions in pathological bone shape change (Abstract 254 in Osteoarthritis and Cartilage Vol. 30 S193).

About OrthoTrophix, Inc.
OrthoTrophix, Inc., based in the San Francisco Bay Area, California, is a privately held biopharmaceutical company focused on development and commercialization of a first-in-class Disease Modifying Osteoarthritis Drug (DMOAD). Founded by three co-founders in 2011, the primary focus of OrthoTrophix has been regeneration and repair of cartilage and underlying bones in the knee and other joints with its novel proprietary compounds.

This press release contains “forward-looking” statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and cannot be guaranteed. OrthoTrophix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect OrthoTrophix’ business.

Company Contact
Yoshi Kumagai
President and CEO
Tel: (510) 488-3824

SOURCE OrthoTrophix, Inc.

###
Originally Appeared Here

Filed Under: joint replacement, ORTHO NEWS

Primary Sidebar

ORTHO NEWS

Spinal anesthesia tied to increased opioid use after hip surgery

Spinal anesthesia tied to increased opioid use after hip surgery

Useful Health Tips for People With Chronic Hip Issues

Useful Health Tips for People With Chronic Hip Issues

A robotic assistant for joint replacement surgery

A robotic assistant for joint replacement surgery

Prior Diagnosis of COVID Has No Increased Complications in Total Joint Arthroplasty

Prior Diagnosis of COVID Has No Increased Complications in Total Joint Arthroplasty

Joint replacement: Myths and facts related to knee replacement surgery | Health

Joint replacement: Myths and facts related to knee replacement surgery

Learn More About Total Hip Arthroplasty and the Function of Robotics in THA

Learn More About Total Hip Arthroplasty and the Function of Robotics in THA

Am I Too Old to Get My Knee or Hip Replaced? What to Consider at Age 70, 80 and Up

Am I Too Old to Get My Knee or Hip Replaced? What to Consider at Age 70, 80 and Up

Putting Your Best Foot Forward for Joint Surgery Success | Health

Putting Your Best Foot Forward for Joint Surgery Success

Use of Antibiotic Lavage in Total Knee Replacement to Prevent Postoperative Infection

Use of Antibiotic Lavage in Total Knee Replacement to Prevent Postoperative Infection

Tips to care for an elderly after hip replacement surgery

Tips to care for an elderly person after hip replacement surgery

Copyright 2014 All Rights Reserved · DISCLAIMER: Nothing here constitutes legal, medical, or other advice; all content relates to an individual perspective only. A professional relationship with a physician, or with a lawyer is built over time, with mutual investment, trust, and respect. This site is not a substitute for that.
~ THIS DOMAIN IS FOR SALE ~

Privacy Policy